28-Mar-2024
Pfizer, Astellas first-line bladder cancer therapy accepted for review in China
Seeking Alpha News (Thu, 28-Mar 11:54 AM ET)
Adobe unveils experimental AI journeys at Las Vegas summit
Seeking Alpha News (Tue, 26-Mar 1:12 PM ET)
Zoetis comes under EU antitrust probe over dog pain drug
Seeking Alpha News (Tue, 26-Mar 12:04 PM ET)
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha News (Tue, 26-Mar 7:37 AM ET)
InvestorBrandMedia (Thu, 21-Mar 7:20 PM ET)
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
Business Wire (Wed, 20-Mar 10:00 AM ET)
Business Wire (Wed, 13-Mar 4:00 AM ET)
Business Wire (Tue, 12-Mar 6:45 AM ET)
Business Wire (Wed, 6-Mar 12:05 PM ET)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Business Wire (Tue, 5-Mar 10:00 AM ET)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer trades on the NYSE stock market under the symbol PFE.
As of March 28, 2024, PFE stock price declined to $27.75 with 32,126,687 million shares trading.
PFE has a beta of 0.35, meaning it tends to be less sensitive to market movements. PFE has a correlation of 0.04 to the broad based SPY ETF.
PFE has a market cap of $156.63 billion. This is considered a Large Cap stock.
Last quarter Pfizer reported $14 billion in Revenue and $.10 earnings per share. This beat revenue expectation by $39 million and exceeded earnings estimates by $.32.
In the last 3 years, PFE stock traded as high as $61.71 and as low as $25.61.
The top ETF exchange traded funds that PFE belongs to (by Net Assets): VTI, VOO, SCHD, SPY, IVV.
PFE has underperformed the market in the last year with a price return of -26.9% while the SPY ETF gained +33.6%. PFE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.5% and -1.7%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
PFE support price is $27.35 and resistance is $28.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFE stock will trade within this expected range on the day.